

CONTENTS

PAGE

| | |
|---|----|
| Chapter I—TERMS OF REFERENCE..... | 5 |
| Chapter II—BACKGROUND TO THE REPORT..... | 6 |
| 1. The Basic Principles..... | 6 |
| 2. Material Available..... | 6 |
| 3. Introduction of Medicare and other Health Services..... | 7 |
| Chapter III—THE DRUG INDUSTRY IN CANADA..... | 8 |
| 1. Types of Industry..... | 8 |
| 2. Control of the Industry..... | 9 |
| 3. Drug Manufacturers..... | 9 |
| 4. Nomenclature in the Industry..... | 11 |
| 5. Profits in the Industry..... | 12 |
| 6. Regulatory Control of the Industry..... | 13 |
| 7. The Hilliard Report and the Boyd Report..... | 14 |
| Chapter IV—COST OF DRUGS TO THE CANADIAN CONSUMER..... | 14 |
| Chapter V—THE ROLE OF THE PHYSICIAN, THE HOSPITAL AND THE GOVERNMENT IN DRUG USAGE..... | 16 |
| 1. The Physician..... | 16 |
| 2. The Hospital..... | 17 |
| 3. The Governments— | |
| (a) Federal..... | 18 |
| (b) Provincial..... | 18 |
| Chapter VI—FACTORS AFFECTING DRUG COSTS AND PRICES..... | 18 |
| 1. At the Manufacturer's Level..... | 18 |
| (a) Anti-Dumping Duties and Tariffs..... | 18 |
| (b) Marketing and Promotional Expenses..... | 19 |
| (c) Brand Names..... | 23 |
| (d) Research and Development..... | 24 |
| (e) Maintenance of Special Drugs for Special Purposes..... | 28 |
| (f) Drug Safety and Quality Control..... | 28 |
| (g) The Federal Sales Tax..... | 29 |
| 2. At the Wholesale Level..... | 31 |
| 3. At the Retail Level..... | 33 |
| 4. Drug Patents and Compulsory Licensing..... | 37 |
| 5. Trade Marks..... | 45 |
| 6. Necessity for Price Competition..... | 46 |
| Chapter VII—OTHER PROPOSALS MADE AND CONSIDERED..... | 47 |
| 1. A National Drug Formulary..... | 47 |
| 2. Appeals from the Decisions of the Food and Drug Directorate... .. | 48 |
| 3. Insurance Plans for Drug Prescriptions..... | 48 |
| 4. Abolition of "Suggested List" Prices..... | 48 |
| 5. Drug Price Restraint Programme..... | 49 |
| 6. A Drug Institute for Canada..... | 49 |
| 7. Ten-Year Moratorium on Drug Patents..... | 50 |
| 8. Triple Damages in Patent Actions..... | 51 |
| 9. Patent Actions and the Exchequer Court..... | 51 |
| 10. Circumvention of the Food and Drug Directorate..... | 51 |
| 11. Other Recommendations of the Hall Commission..... | 51 |